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On April 1, 2016, the Centers for Medicare and Medicaid Services (CMS) implemented the Comprehensive Care for Joint Replacement (CJR) model for 67 major metropolitan areas in the United States. According to the CMS, "The CJR model aims to support better and more efficient care for beneficiaries undergoing the most common inpatient surgeries for Medicare beneficiaries: hip and knee replacements (also called lower extremity joint replacements)" (1) . To accomplish these objectives, the CJR uses quality metrics and bundled payments that encompass an episode of joint replacement care, which begins with the index admission and ends 90 days after discharge.
Although primary total hip (THA) and knee (TKA) arthroplasty are the most common inpatient surgeries for Medicare beneficiaries, hip hemiarthroplasty and total ankle arthroplasty (TAA) are also included in the CJR under the umbrella definition of lower extremity joint replacement. Hip hemiarthroplasty is almost exclusively reserved for the treatment of acute hip fractures. In contrast, THA and TKA are treatments for chronic joint degeneration. The CJR acknowledges that geriatric hip fracture patients have differences in their general medical condition and short-term healthcare resource usage compared with elective joint replacement patients and has therefore stratified its reimbursements to providers for the presence of a hip fracture (2, 3) .
During the feedback period for the proposed CJR rule, the American Academy of Orthopaedic Surgeons and the American Orthopaedic Foot and Ankle Society (AOFAS) urged the CMS to reconsider the inclusion of TAA in the CJR (4,5). Similar to hip fracture patients who undergo hip hemiarthroplasty, patients with end-stage ankle arthritis who undergo TAA were believed to represent a different patient population with different healthcare needs than those undergoing THA and TKA. The specific differences cited by the AOFAS included the greater implant costs, longer operating times, increased procedure complexity, and prolonged immobilization necessitating greater usage of postoperative acute care services (5) . Despite these concerns about TAA, the CMS ultimately considered it equivalent to THA and TKA in the final CJR rule (3) .
We share many of the same concerns as the American Academy of Orthopaedic Surgeons and AOFAS about TAA's inclusion in the CJR. However, we were unable to identify any previous studies that directly compared the short-term clinical and economic outcomes of TAA versus elective primary THA and TKA. Therefore, we conducted a retrospective cohort study to explore the differences between these procedures regarding the (1) length of stay of the index admission; (2) cost of the index admission; (3) rate of disposition to nursing and rehabilitation facilities; and (4) rate of 90-day readmission.
Materials and Methods

Study Design and Setting
The New York Statewide Planning and Research Cooperative System (SPARCS) is a comprehensive healthcare data reporting system established by the New York State Department of Health. This database contains all hospital admissions that occur within New York State annually. Each record includes the patient demographics and details of the clinical course, including medical diagnoses and surgical procedures. The database creates a unique identification code for each patient, allowing researchers to retrospectively monitor patients. Because our version of the SPARCS database does not contain any protected health information, our institutional review board determined the present study was exempt from informed consent. The investigation was performed at SUNY Downstate Medical Center (Brooklyn, NY) and NYU Hospital for Joint Diseases (New York, NY).
Study Subjects
The study cohort flowchart is shown in the We excluded patients with an ICD-9 diagnosis code of hip fracture as defined by the CJR, those with primary ICD-9 diagnosis codes excluded from coverage by the CJR, and patients with <90 days of follow-up (1). With some patients accounting for multiple exclusions, our final study cohort consisted of 229,538 patients.
Variables
We extracted patient demographic data, including age (in years), sex (male or female), race (white or nonwhite), insurance (Medicare/Medicaid or private/other) and year of admission (2009 through 2014). Comorbidities were assessed using the Charlson/ Deyo scoring method for ICD-9 coding (6).
For the index admission, the outcomes included the length of stay, cost, and disposition to a nursing or rehabilitation facility. During the follow-up period, our outcome of interest was 90-day readmission to a New York State hospital with an MS-DRG code considered surgery related by the CJR (1). Costs were derived using hospital inpatient cost transparency data provided by the New York State Department of Health (7) and expressed in 2016 US dollars using inflation rates from the Consumer Price Index (8) . For each All Patient Refined Diagnosis-Related Group and its 4 levels of severity of illness for a given hospital in a given calendar year, we defined the cost-to-charge ratio as the mean cost of admission divided by the mean charge of admission.
Statistical Analysis
We used frequency tables and proportions to describe the patient characteristics stratified by the type of lower extremity joint replacement. We calculated the significance of differences in each variable using Fisher exact tests for binary variables and χ 2 tests for multilevel categorical variables. For the 6 p values we reported (Table 1) , we used the Holm-Bonferroni method to correct for multiple comparisons (9) .
We used geometric mean values to report averages in length of stay and cost. Geometric means were selected over arithmetic means because they are less influenced by outlier values. To calculate the magnitude and significance of differences in the length of stay and cost, we used mixed effects linear regression models. We performed logarithmic transformations on the length of stay and cost in these regression models to normalize the variables' right-skewed distributions and assigned a value of 0.001 to outcomes equal to 0 days or $0. We interpreted the regression coefficients and 95% confidence intervals (CIs) as the percentage of differences using the formula 100 × (e b − 1), where b is the parameter estimate of a log-transformed outcome variable (10) .
We used frequency tables with proportions to describe the disposition and readmission rates. For these values, we calculated exact (Clopper-Pearson) 95% CIs using binomial proportions. To calculate the magnitude and significance of differences in disposition and readmission, we used mixed effects logistic regression models to calculate odds ratios and 95% CIs. We interpreted these values as the percentage of differences in risk using the formula 100 × (odds ratio − 1).
All mixed effects regression models used THA and TKA as the reference group. The models were controlled for hospital and year of surgery as random effects variables and categorical age, sex, race, insurance, categorical Charlson/Deyo score, and MS-DRG as fixed effects variables. For the 4 p values we reported from the mixed effects regression models in our primary analysis, we used the Holm-Bonferroni method to correct for multiple comparisons (9) . In secondary analyses, we performed each analysis on the subset of Medicare patients undergoing TAA versus THA and TKA. We performed all statistical analyses using SAS version 9.4 (SAS Institute Inc., Cary, NC). 
Results
Demographic Data
The cohort included 510 TAA, 91,010 THA, and 138,018 TKA procedures. For TAA compared with THA/TKA, significant differences were found in age (p < .001), sex (p = .001), race (p = .005), insurance (p < .001), Charlson/Deyo comorbidity score (p = .049), and MS-DRG (p = .003; Table 1 ).
Length of Stay
The mean length of stay was 2.2 (95% CI 2.0 to 2.3) days for TAA and 3.2 (95% CI 3.2 to 3.2) days for THA/TKA. On multivariableadjusted regression modeling, the length of stay was 30% shorter (95% CI −32% to −28%) for TAA compared with THA/TKA (p < .001; Table 2 ).
Cost of Admission
The mean cost of admission was $20,817 (95% CI $20,129 to $21,528) for TAA and $17,613 (95% CI $17,583 to $17,644) for THA/TKA. On multivariable-adjusted regression modeling, the cost of admission was 14% greater (95% CI 12% to 16%) for TAA compared with THA/TKA (p < .001; Table 2 ).
Disposition to Facility
The rate of disposition to a nursing or rehabilitation facility was 17% (95% CI 14% to 20%) for TAA and 52% (95% CI 52% to 52%) for THA/ TKA (Tables 2 and 3 ). On multivariable-adjusted regression modeling, the risk of disposition to nursing and rehabilitation facilities was 86% lower (95% CI −90% to −82%) for TAA compared with THA/TKA (p < .001; Table 2 ).
Readmission
The rate of 90-day readmission was 4.9% (95% CI 3.2% to 7.2%) for TAA and 5.8% (95% CI 5.7% to 5.9%) for THA/TKA ( Table 2 ). The most common reason for readmission after TAA was postoperative infection (Table 4) . On multivariable-adjusted regression modeling, the risk of 90-day readmission was not significantly different for TAA versus THA/TKA (p = .957; Table 2 ).
Secondary Analyses
Among the subset of Medicare patients, those undergoing TAA had shorter mean length of stay (2.5 versus 3.3 days), higher mean cost ($22,155 versus $17,754), lower rates of disposition to nursing and rehabilitation facilities (28% versus 66%), and lower 90-day readmission rates (4.3% versus 7.3%). In mixed effects models of TAA versus THA and TKA among Medicare patients, the length of stay was 22% shorter (p < .001), costs were 18% greater (p < .001), and the risk of disposition to nursing and rehabilitation facilities was 81% less (p < .001). The risk of 90-day readmission was not significantly different (p = .337; Table 5 ).
Discussion
During the next 5 years, the CJR will test the feasibility and efficacy of bundled payments for primary hip, knee, and ankle Other facility 3 (5948) 1 (3) Data presented as % (n). Percentages might not sum to 100% because of rounding.
replacement. Although THA and TKA are the most common inpatient surgeries for Medicare enrollees, TAA accounts for <1% of all primary lower extremity joint replacements. Compared with THA and TKA, TAA is characterized by shorter but more expensive hospital stays, with greater rates of discharge to home. Payers and providers should note these different patterns in short-term resource usage for TAA as they design and test alternative payment models for joint replacement care.
Study Limitations
We acknowledge that our study had several limitations. First, the SPARCS database does not contain information on certain patient characteristics, including body mass index and American Society of Anesthesiologists score; intraoperative data, including length of surgery and type of anesthesia; or certain postoperative outcomes, including functional and ambulatory status. Second, the costs were calculated using cost-to-charge ratios and were not directly measured. Furthermore, our reported costs of admission for TAA were greater than previously reported, although we suspect that these increases were secondary to inflation from more recent data and increased fixed operating costs in New York compared with the rest of the United States (11, 12) . Third, the SPARCS database does not include claims data for rehabilitation, nursing, or home care services. Therefore, we were unable to calculate the costs for the entire episode of care as defined by the CJR, which includes the index admission and the 90-day postoperative period. Such data are relevant to furthering our understanding of the patterns of resource usage for each type of arthroplasty.
Length of Stay
We observed that the length of stay was shorter for TAA than for THA and TKA. This finding is consistent with a series of studies using Medicare claims data in the late 2000s, which reported mean lengths of stay of 2.3 days for TAA, 3.7 days for THA, and 3.5 days for TKA (13) (14) (15) . Other recent studies focusing specifically on TAA have reported similar findings, with mean lengths of stay of 2.2 days and 2.5 days (12, 16) . After any joint replacement, clearance for hospital discharge is dependent on medical stability, pain control, and ambulation. Intraoperative blood loss is a common cause of medical instability for THA and TKA, with transfusion rates of 10% to 20% (17) . In contrast, TAA patients have considerably lower risks of blood loss, with transfusion rates of~1% (18) . Patients undergoing TAA are also subject to quicker discharge because they will be non-weightbearing in the postoperative period and therefore do not require intensive inpatient physical therapy services, which are routinely needed for THA and TKA. Similarly, TAA patients are more likely to be discharged to home than are THA and TKA patients, decreasing the likelihood of prolongations in length of stay related to waiting for approval and transfer to nursing and rehabilitation facilities. Finally, conditions, including diabetes, peripheral neuropathy, and obesity, are contraindications to TAA, with TAA candidates generally healthier than THA/TKA patients and, subsequently, less likely to have a medical issue prolonging their stay. Moving forward, we expect that the gap in length of stay will widen, with the increasing use of regional nerve blocks and 23-hour outpatient admissions.
Cost
Although TAA patients were subject to shorter hospital stays than THA and TKA, the costs of these admissions were significantly greater for TAA. Implant costs are suspected to play a significant role, with a previous Canadian study reporting that TAA implants are twice as expensive as THA and TKA implants (19) . Similarly, in the United States, implant costs range from $8700 to $9500 for TAA compared with $2000 to $12,000 for THA and TKA (11, 20) . One suspected explanation is the relatively low volume of TAA procedures performed, which decreases the ability of hospitals to negotiate with industry on implant costs. Other potential causes of the increased costs for TAA include the longer operating times with adjunct soft tissue or bony procedures used to restore alignment and balance in the foot (19) .
Disposition
As noted, TAA patients were less likely to be discharged to nursing or rehabilitation facilities, consistent with the rehabilitation protocols used for this procedure. Postoperatively, TAA patients are kept non-weightbearing and immobilized in a short-leg splint or cast for 2 to 4 weeks. If medically and functionally stable, they can be discharged home and begin outpatient rehabilitation at~6 weeks postoperatively (21) . In contrast, many THA and TKA patients are allowed to weight bear immediately after surgery. Once medically stable, they can begin rehabilitation within 24 hours of surgery and continue this intensive rehabilitation therapy in a skilled nursing facility, acute rehabilitation facility or as an outpatient (22) (23) (24) . With rehabilitation services higher in acuity for THA and TKA but longer in duration for TAA, further study is needed to evaluate the costs and usage of these services for the entire episode of joint replacement care.
Readmission
The rate of 90-day readmission was lower for TAA than THA/TKA patients, although this difference was not statistically significant. The most common indication for readmission was infection, followed by lower extremity reoperation. The medical complications common to THA and TKA, including deep venous thrombosis, pulmonary embolism, and myocardial infarction, were uncommon for TAA patients and surgical complications such as periprosthetic fracture and dislocation were nonexistent. Given the limited statistical power of our analysis, however, further study is needed to definitively elucidate the differences in readmission between TAA and THA/TKA.
In conclusion, patients undergoing TAA have different patterns of short-term resource usage compared with patients undergoing THA and TKA, most notably greater short-term costs. Given these findings, we strongly believe that TAA does not belong in the CJR. TAA has become an efficacious and cost-effective treatment for patients with end-stage stage ankle osteoarthritis (11, 25) . However, the economic viability of this procedure is now threatened by alternative payment models such as the CJR that reimburse hospitals for TAA at the same rate as they reimburse for THA and TKA. In the absence of policy changes, we encourage hospitals and providers to identify sources of inefficiency, cost savings, and quality improvement for TAA. Clinical care pathways have been shown to decrease costs and improve outcomes for THA and TKA. However, these types of initiatives have not been previously described for TAA (26) and should be explored in future studies.
